Cosmos Health expands its Sky Premium Life partnership with Pharma Cell in Albania, with average monthly orders already exceeding 4,500 units, and projected to exceed 54,000 annually Products are distributed across

COSM

Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units

Cosmos Health expands Sky Premium Life in Albania with Pharma Cell, targeting 54k annual units

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Cosmos Health expands its Sky Premium Life partnership with Pharma Cell in Albania, with average monthly orders already exceeding 4,500 units, and projected to exceed 54,000 annually Products are distributed across</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Cosmos Health announced an expanded Sky Premium Life distribution agreement with Pharma Cell in Albania, building on a April 2025 launch. Current orders exceed 4,500 per month and are projected to exceed 54,000 units annually, supported by doctor referrals. The expansion signals stronger market uptake in Albania and could lift near-term revenue and branding in Europe.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Cosmos Health expands Sky Premium Life with Pharma Cell in Albania; orders exceed 4,500 monthly.</li><li>Products distributed across Albania; doctors and healthcare professionals recommend Sky Premium Life.</li><li>Expansion follows April 2025 launch; Albanian market momentum supports growth.</li><li>CEO Greg Siokas cites continued growth; partnership strengthening Sky Premium Life&#039;s footprint.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Cosmos Health Inc. (COSM)</strong>: Expands Sky Premium Life distribution in Albania via Pharma Cell; potential near-term revenue uplift.</li><li><strong>Pharma Cell (Private)</strong>: Albania-based distributor; expansion broadens Sky Premium Life coverage and doctor-endorsed access.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. The article reports a strategic partnership expansion that could affect Cosmos Health&#039;s regional revenue growth and brand presence, fitting corporate development analysis.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Expanded Albania deal boosts Sky Premium Life revenue trajectory.</li><li>54,000 annual units target implies meaningful European top-line potential.</li><li>Doctor-recommended products support demand stability and broader access.</li><li>Regulatory or supply delays could delay revenue realization.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Partnership expansion announced July 20, 2026.</li><li>Average monthly orders exceed 4,500 units.</li><li>Annualized orders expected to exceed 54,000 units.</li><li>Partnership launched in April 2025.</li><li>Pharma Cell is based in Tirana, Albania.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>COSM could see near-term revenue uplift from the Albania expansion; monitor results in 1–3 quarters.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><ul><li style="text-align:left;">Cosmos Health expands its Sky Premium Life partnership with Pharma Cell in Albania, with average monthly orders already exceeding 4,500 units, and projected to exceed 54,000 annually </li><li style="text-align:left;">Products are distributed across Albania and recommended by doctors and healthcare professionals, supporting broad consumer access</li><li style="text-align:left;">Expansion builds on the partnership launched in April 2025 and reflects Sky Premium Life&#39;s continued global growth<br></br><br></br></li></ul>  <p align="left">CHICAGO, July  20, 2026  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=9BD6gQZKm4f89GfnB6Dz_E3Pvz5dLkXYZQc9aaFITygGoaCPdK-oncYVF05umERaOo9xxnaBbLz0zxk0e4eLMXYnaeu3Gr8mUF7focmeEu8=" rel="nofollow" target="_blank"><strong><u>Cosmos Health Inc.</u></strong></a><strong> (&#34;Cosmos Health&#34; or the "Company") </strong><a href="https://www.globenewswire.com/Tracker?data=9zpEokUDoNCVz567g8QS9wjVIyDduMGUqGD6qz2_VLmxxMkyRxkwEQ83rTDTKjHZb6hrjQ5_M3c6KoTf6tXkKxHkwV-nHr4qxZUs8HXVAcU=" rel="nofollow" target="_blank"><strong><u>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COSM">COSM</a>)</u></strong></a>, a diversified, vertically integrated global healthcare group, today announced an expansion of its partnership with <a href="https://www.globenewswire.com/Tracker?data=d7xCvo38GacFgLbl5KijwwwusNxe6Exi4v54aqGYGjwc__qRMTn_AOsTXUmSl_I_0sgIpxJEtpR5sVPFsQikmQ==" rel="nofollow" target="_blank"><u>Pharma Cell</u></a> for the distribution of its Sky Premium Life brand in Albania.</p>  <p align="center"><img alt="Sky Premium Life continues its international growth — available across Albania in partnership with Pharma Cell." height="600" src="https://ml.globenewswire.com/Resource/Download/ebd53432-c3fe-4c29-a913-0ee0c41ad3eb/260720-cosmos-photo.jpeg" width="450" data-dpi="96" data-caption="Sky Premium Life continues its international growth — available across Albania in partnership with Pharma Cell." data-filename="260720_Cosmos_photo.jpeg"></img><br></br></p>  <p align="left">Building on the partnership the companies launched in April 2025, and reflecting the strong reception of Sky Premium Life in the Albanian market, the Company anticipates that orders under the expanded relationship will exceed 54,000 units on an annualized basis, with average monthly orders already exceeding 4,500 units. The products are distributed across Albania and are recommended by doctors and healthcare professionals, supporting broad access for consumers across the country.</p>  <p align="left">Pharma Cell, based in Tirana, is a fast-growing pharmaceutical company specializing in high-quality food supplements, with an established distribution network serving pharmacies and healthcare professionals across Albania. The momentum is strong as Sky Premium Life continues its global expansion.</p>  <p align="left"><strong>Greg Siokas, CEO of Cosmos Health, stated:</strong> &#34;The growth of our partnership with Pharma Cell reflects the strong momentum of Sky Premium Life in Albania. Backed by recommendations from doctors and healthcare professionals, our products are reaching a broad population, and we look forward to continuing to grow the brand&#39;s presence in the market alongside Pharma Cell.&#34;</p>  <p align="left"><strong>About Cosmos Health Inc.</strong></p>  <p align="left">Cosmos Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/COSM">COSM</a>), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life&#xAE;, Mediterranation&#xAE;, bio-bebe&#xAE;, C-Sept&#xAE; and C-Scrub&#xAE;. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&amp;D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&amp;D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at <a href="https://www.globenewswire.com/Tracker?data=yXFEzd_hwUrz6-Za0REWF0X2-od6R6FH4DxpRE92WkDf8MIrPh-zoVRixEDrL7AiQUk6b0KYfrUcQ9ibO9gxnzYZBUK1r8BCaP6OoJo33uyYmZVCThgaA70NyXFsw32D" rel="nofollow" target="_blank"><u>www.cosmoshealthinc.com</u></a>, <a href="https://www.globenewswire.com/Tracker?data=r4xfKyEoaaAnPtN75MNtLf1AZUnpzsVe-s3UmumGqMbNOs7jkRr-Awl6EvyK_3ytUk0CIsSh2MnOHCFL-5fPViX9UrDlRK4Tli6kIdxWxb0=" rel="nofollow" target="_blank"><u>www.skypremiumlife.com</u></a>, <a href="https://www.globenewswire.com/Tracker?data=OuogPYzAcVBi9Bj2mEBvdvTVUxnmnFR2JPQE86Ds59ZaOxDhUaJiZRCwewR2b3Nd5Oa5jtKdoBMcruLjziidQg==" rel="nofollow" target="_blank"> <u>www.cana.gr</u></a>, <a href="https://www.globenewswire.com/Tracker?data=trI0k6CoZ1cp15GQG1kajTJej1ZDKw4ZvdajcN3-F8emyvzEls2hU_0mY1_1oQUcVvOyKceGXMY8byoY72OkUeuQ_qkeirzDYQbg-d1uekU=" rel="nofollow" target="_blank"><u>www.zipdoctor.co</u></a>, <a href="https://www.globenewswire.com/Tracker?data=yXFEzd_hwUrz6-Za0REWF5uRVQwjcE1-xn4OihDwEFKlLcKQk6bCVjJzH1JwpEBZ6hVDBAcCp9aI7CW7d7NmmJgh71ERNDIa9IDvrHL6iro=" rel="nofollow" target="_blank"><u>www.cloudscreen.gr</u></a>, as well as<a href="https://www.globenewswire.com/Tracker?data=00OxS8dYupcF0OD7griZ8WiJ6zMYPak2T62e4JTz21GbiACbFjNB3NhHF2Z-IbVsOO-xLwECseidCKeFRxmeufPc7dYWlVio6TOIoOnvygNG0s_XM7a1QDFHl4AuUhxs" rel="nofollow" target="_blank"> <u>LinkedIn</u></a> and <a href="https://www.globenewswire.com/Tracker?data=nMcKt60ZgVnywSYxRMIJ8lm9Z86dCBSN7hFrYBUBmCMGNqIELfwwI1t0JzXyk0tcLLRIO5p3fjUCPYZxGeAiH0QNhDLBGmk2yaNIFo5yHRY=" rel="nofollow" target="_blank"><u>X</u></a>.</p>  <p align="left"><strong>Forward-Looking Statements</strong><br></br>With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (<a href="https://www.globenewswire.com/Tracker?data=r4xfKyEoaaAnPtN75MNtLRFrToDGwSBuwSwcl4-VTTgHJA9-KeYUHzo_QO4pdaXeYGlNDCsS0yZxOrrt2M3VaA==" rel="nofollow" target="_blank"><u>www.sec.gov</u></a>). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.</p>  <p align="left"><strong>Investor Relations Contact:</strong><br></br>BDG Communications<br></br>cosm@bdgcommunications.com</p>  <p align="left">An image accompanying this announcement is available at <a href="https://www.globenewswire.com/Tracker?data=8Ytk1QoKjksaoSE2SvV3ogHilb8GiDTZxCHB08eLcX9Gxi0tV0U16nz_weXHy42EGPoVX45ZBi_3eOSpM6S6Ed0q2FF_QOcJjTwcErgmXsX834xxy8WYx3k2DNkc2-4BP2I2bEwSWvb38baieQ-iyAjYQnh9fd-pqmqAZldsrJ3BSHDYZq9laqHiS57LYPHnVxq8D58CM457lah4SSSfYPc35DszUk0Hx7FuqSzzn4qOCdg2ONQOmHQciHpoiV3ZeUdMECVQfytdFJsPoHh0fw==" rel="nofollow" target="_blank">https://www.globenewswire.com/NewsRoom/AttachmentNg/ebd53432-c3fe-4c29-a913-0ee0c41ad3eb</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTc2NTAzMiM3NzE0MjkwIzIyOTgwOTQ="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NjQ3NDA3Y2MtMTg0NC00N2Q3LTgxN2UtZWZmMTc4YzM5ZWU2LTEzMDk2NDQtMjAyNi0wNy0yMC1lbg==/tiny/Cosmos-Health-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/29681d62-58aa-4ccf-bad9-cb7ce8ae66e4"><img src="https://ml.globenewswire.com/media/29681d62-58aa-4ccf-bad9-cb7ce8ae66e4/small/cosmos-png.png" border="0" width="150" height="78" alt="Primary Logo"></img></a></p>

Cosmos Health announced an expanded Sky Premium Life distribution agreement with Pharma Cell in Albania, building on a April 2025 launch. Current orders exceed 4,500 per month and are projected to exceed 54,000 units annually, supported by doctor referrals. The expansion signals stronger market uptake in Albania and could lift near-term revenue and branding in Europe.

Cosmos Health Expands Pharma Cell Partnership in Albania with Annualized Orders Projected to Exceed 54,000 Units

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News